We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lonafarnib

News List

FDA Approves Zokinvy for Hutchinson-Gilford Progeria Syndrome americanpharmaceuticalreview
December 08, 2020
Eiger BioPharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved ZokinvyTM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).
New Drug Application submitted for first-ever Progeria treatment europeanpharmaceuticalreview
December 23, 2019
A New Drug Application has been submitted to the FDA for lonafarnib, the first-ever treatment for Progeria and Progeroid Laminopathies.
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib americanpharmaceuticalreview
December 19, 2018
Eiger BioPharmaceuticals announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lonafarnib for the treatment of hepatitis delta virus (HDV) infection......
Eiger Announces FDA Acceptance of IND Application for Lonafarnib americanpharmaceuticalreview
December 05, 2018
Eiger BioPharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for lonafarnib....